Lantheus Medical Imaging Awarded Three-Year Supplier Agreement with the Premier Healthcare Alliance for Radiopharmaceutical Products
Supplier Agreement Provides More Than 2,500 Member
Hospitals Nationwide with Access to Cardiac, Brain and Lung Imaging Agents
No. BILLERICA, Mass. (October 24, 2011) – Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, today announced it has been awarded a three-year supplier contract with Premier Purchasing Partners, L.P., the group purchasing unit of the Premier healthcare alliance, for its radiopharmaceutical imaging agents. Effective January 1, 2012 through December 31, 2014, the new radiopharmaceutical products agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), Gallium 67 (Gallium Citrate Ga67 Injections), Neurolite® (Kit of the Preparation of Technetium Tc99m Bicisate for Injection), TechneLite® (Technetium Tc99m Generator), 201 Thallium (Thallous Chloride Tl201 Injection) and Xenon 133 (Xenon Xe 133 Gas).
Lantheus’ radiopharmaceutical products will be offered through a specially negotiated contract to more than 2,500 hospitals nationwide and 76,000-plus healthcare sites. The contract was awarded after a competitive bidding process that examined multiple factors, including pricing and clinical experience with the diagnostic imaging agents, as well as Lantheus’ support of the products.
“We are excited to announce that Premier has awarded Lantheus with a three-year supplier agreement for our nuclear imaging products,” said Don Kiepert, President and Chief Executive Officer, Lantheus Medical Imaging. “These important agents are critical to helping clinicians assess patients for cardiac disease, stroke, cancerous tumors and pulmonary function. We are pleased that, once again, Premier has selected Lantheus as a preferred supplier to its members.”
Please visit www.lantheus.com for full Prescribing Information.
About Lantheus Medical Imaging, Inc.
Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, is dedicated to creating and providing pioneering medical imaging solutions to improve the treatment of human disease. The Company’s proven success in the field of diagnostic imaging provides a strong platform from which to bring forward breakthrough new tools for the diagnosis and management of disease. Lantheus imaging products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension, an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, ABLAVAR® (gadofosveset trisodium), a first-in-class magnetic resonance agent indicated for the evaluation of aortoiliac occlusive disease in adults with known or suspected peripheral vascular disease, TechneLite® (Technetium Tc99m Generator), Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), and Thallium 201 (Thallous Chloride Tl 201 Injection). Lantheus has approximately 600 employees worldwide with headquarters in North Billerica, Massachusetts, and offices in Puerto Rico, Canada and Australia. For more information, visit www.lantheus.com.
About the Premier Healthcare Alliance, Malcolm Baldrige National Quality Award Recipient
Premier is a performance improvement alliance of more than 2,500 U.S. hospitals and 76,000-plus other healthcare sites using the power of collaboration to lead the transformation to high quality, cost-effective care. Owned by hospitals, health systems and other providers, Premier maintains the nation's most comprehensive repository of clinical, financial and outcomes information and operates a leading healthcare purchasing network. A world leader in helping deliver measurable improvements in care, Premier has worked with the Centers for Medicare & Medicaid Services and the United Kingdom's National Health Service North West to improve hospital performance. Headquartered in Charlotte, N.C., Premier also has an office in Washington.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties that may be described from time to time in our filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.